1. ANGI-09. BEVACIZUMAB IN ATYPICAL AND ANAPLASTIC MENINGIOMAS: THE BEMEN STUDY. (14th November 2022) Authors: Cerretti, Giulia; Bosio, Alberto; Maccari, Marta; Padovan, Marta; Caccese, Mario; Zagonel, Vittorina; Lombardi, Giuseppe Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BIOM-19. NEXT-GENERATION SEQUENCING (NGS) FOR IDENTIFYING ACTIONABLE MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED AND RECURRENT IDHWT-GLIOBLASTOMA (GBM) PATIENTS: A LARGE MONO INSTITUTIONAL EXPERIENCE. (14th November 2022) Authors: Padovan, Marta; Maccari, Marta; Bosio, Alberto; Vizzaccaro, Salvatore; Cestonaro, Ilaria; Corrà, Martina; Caccese, Mario; Cerretti, Giulia; Fassan, Matteo; Zagonel, Vittorina; Lombardi, Giuseppe Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BIOM-21. THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY. (12th November 2021) Authors: Lombardi, Giuseppe; Giunco, Silvia; Cavallin, Francesco; Angelini, Chiara; Caccese, Mario; Cerretti, Giulia; De Bonis, Pasquale; De Rossi, Anita; Zagonel, Vittorina Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CTNI-12. PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS: THE RACTAC TRIAL. (14th November 2022) Authors: Pace, Andrea; Lombardi, Giuseppe; Matteoni, Silvia; Villani, Veronica; Benincasa, Dario; Abruzzese, Claudia; Cerretti, Giulia; Caccese, Mario; Silvani, Antonio; Paggi, Marco Giorgio Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CTNI-12. PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS SYNERGISM WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS: THE RACTAC TRIAL. (12th November 2021) Authors: Pace, Andrea; Lombardi, Giuseppe; Matteoni, Silvia; Villani, Veronica; Abruzzese, Caludia; Cerretti, Giulia; Padovan, Marta; Caccese, Mario; Benincasa, Dario; Silvani, Antonio; Paggi, Marco Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY. (12th November 2021) Authors: Bosio, Alberto; Cerretti, Giulia; Padovan, Marta; Caccese, Mario; Guarneri, Valentina; Zagonel, Vittorina; Lombardi, Giuseppe Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CTNI-50. REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: A LARGE REAL-LIFE EXPERIENCE. (12th November 2021) Authors: Caccese, Mario; Cerretti, Giulia; Padovan, Marta; Zagonel, Vittorina; Lombardi, Giuseppe Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification. Issue 1 (10th August 2022) Authors: Cerretti, Giulia; Cecchin, Diego; Denaro, Luca; Caccese, Mario; Padovan, Marta; Zagonel, Vittorina; Lombardi, Giuseppe Journal: Anti-cancer drugs Issue: Volume 34:Issue 1(2023) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. Issue 2 (4th March 2023) Authors: Padovan, Marta; Cerretti, Giulia; Caccese, Mario; Barbot, Mattia; Bergo, Eleonora; Occhi, Gianluca; Scaroni, Carla; Lombardi, Giuseppe; Ceccato, Filippo Journal: Expert review of endocrinology & metabolism Issue: Volume 18:Issue 2(2023) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗